

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Modern Chinese Medicine Group Co., Ltd.**

**現代中藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1643)**

### **CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The board of directors (the “**Board**” and the “**Directors**” respectively) of Modern Chinese Medicine Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that due to the personal work redeployment, Ms. Chan Tsz Hei Sammi (formerly known as Chan Wan Ling Sammi) (“**Ms. Chan**”) has tendered her resignation as (i) a joint company secretary of the Company; (ii) an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) the authorised representative of the Company to accept service of process and notices in Hong Kong (“**Process Agent**”), all with effect from the date of this announcement.

Ms. Chan has confirmed that she has no disagreement with the Board and there is no other matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and/or the shareholders of the Company.

Following the resignation of Ms. Chan, the Board announces that Ms. Tse Yuen Ting (“**Ms. Tse**”) has been appointed as (i) a joint company secretary of the Company; (ii) an authorised representative of the Company under Rule 3.05 of the Listing Rules; and (iii) the Process Agent, all with effect from the date of this announcement. Ms. Jia Yanyu (“**Ms. Jia**”) will continue to serve as another joint company secretary of the Company.

The biographical details of Ms. Jia are set out as follows:

Ms. Jia was appointed as deputy general manager (finance) of the Company (“**Deputy GM**”) in August 2021 and a joint company secretary of the Company on 30 August 2023. She is responsible for secretarial and compliance matters, the management of financial, supervisory and compliance as well as investor relation matters and possesses experience in financial management in pharmaceutical industry for more than 20 years. Ms. Jia joined the Group in 2004 and prior to being promoted as Deputy GM, Ms. Jia was a finance manager of the Group.



Ms. Jia graduated from the Northeast Normal University (東北師範大學), the Mainland China with a Higher Education Graduation Certificate (major in accounting) (高等教育畢業證書 (會計專業)).

The biographical details of Ms. Tse are set out as follows:

Ms. Tse is a practising solicitor admitted in the Hong Kong Special Administrative Region and a member of the Law Society of Hong Kong, who possesses a Postgraduate Certificate in Laws and a Juris Doctor degree from the City University of Hong Kong.

### **Waiver From Strict Compliance with the Requirements Under Rules 3.28 and 8.17 of the Listing Rules**

Reference is made to the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Ms. Jia to act as a joint company secretary for a period of three years commencing on 30 August 2023 (the “**Waiver Period**”), on the condition that Ms. Jia would be assisted by Ms. Chan, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period. Relevant details of the Waiver were disclosed in the announcement of the Company dated 30 August 2023. Given that the condition of the Waiver could no longer be fulfilled following the resignation of Ms. Chan, the Company has applied to the Stock Exchange and has been granted a new waiver (the “**New Waiver**”) by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Waiver Period (the “**Remaining Waiver Period**”) in relation to the eligibility of Ms. Jia to act as a joint company secretary, on the conditions that:

- (i) Ms. Jia must be assisted by Ms. Tse as a joint company secretary throughout the Remaining Waiver Period; and
- (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate to the Stock Exchange and seek for its confirmation that Ms. Jia, having had the benefit of Ms. Tse’s assistance during the Remaining Waiver Period, has attained the relevant experiences and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules, such that a further waiver will not be necessary.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Chan for her valuable contribution to the Company during her tenure of office, and would like to extend its welcome to Ms. Tse on her appointment.

By Order of the Board  
**Modern Chinese Medicine Group Co., Ltd.**  
**Zhang Hongli**  
*Executive Director*

Hong Kong, 10 March 2025

*As at the date of this announcement, the Board comprises three executive Directors, namely Ms. Sun Xinlei, Ms. Zhang Hongli and Ms. Jia Yanru; and three independent non-executive Directors, namely Ms. Liu Ling, Mr. Leung Tsz Wing and Mr. Wong Chi Kin.*